Negative / Null Result ReportOpen accessMedicine· cited by 47

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

Sara Galimberti; Mario Petrini; Claudia Baratè; Federica Ricci; Serena Balducci; Susanna Grassi; Francesca Guerrini; Elena Ciabatti · 2020 · Frontiers in Oncology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML), have been proposed on the basis of their antiviral action already demonstrated against SARS-CoV-1. Very few cases of COVID-19 have been reported in Ph+ ALL and in CML Italian cohorts; authors suggested that this low rate of infections might depend f

Abstract by Sara Galimberti; Mario Petrini; Claudia Baratè; Federica Ricci; Serena Balducci; Susanna Grassi; Francesca Guerrini; Elena Ciabatti, Frontiers in Oncology (2020) — licensed CC BY 4.0.

Read the full paper (open access)